EA199900932A1 - Фармацевтические композиции, обладающие активностью подавления аппетита - Google Patents

Фармацевтические композиции, обладающие активностью подавления аппетита

Info

Publication number
EA199900932A1
EA199900932A1 EA199900932A EA199900932A EA199900932A1 EA 199900932 A1 EA199900932 A1 EA 199900932A1 EA 199900932 A EA199900932 A EA 199900932A EA 199900932 A EA199900932 A EA 199900932A EA 199900932 A1 EA199900932 A1 EA 199900932A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
pharmaceutical compositions
activity suppression
appetite
synthesis
Prior art date
Application number
EA199900932A
Other languages
English (en)
Other versions
EA002885B1 (ru
Inventor
Херден Фани Ретиф Ван
Роберт Влеггар
Рулоф Мартинюс Хорак
Робин Алек Леармонт
Винес Махарай
Рори Десмонд Виттал
Original Assignee
Ссир
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ссир filed Critical Ссир
Publication of EA199900932A1 publication Critical patent/EA199900932A1/ru
Publication of EA002885B1 publication Critical patent/EA002885B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • C07H5/10—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium to sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
    • C07J7/0035—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16 by a hydroxy group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

Фармацевтическая композиция содержит экстракт, получаемый из растения из рода Trichocaulon или Hoodia, и содержащий агент, подавляющий аппетит, имеющий формулу (1). Также разработан способ получения экстракта и способ синтеза соединения (1), его аналогов и производных. Изобретение также распространяется на применение таких экстрактов и соединения (1), его аналогов и производных в производстве медикаментов, обладающих активностью подавления аппетита. Кроме того, это изобретение предоставляет новые промежуточные соединения для синтеза соединения (1).Отчет о международном поиске был опубликован 1999.02.25.
EA199900932A 1997-04-15 1998-04-15 Средства растительного происхождения для подавления аппетита EA002885B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA973201 1997-04-15
PCT/GB1998/001100 WO1998046243A2 (en) 1997-04-15 1998-04-15 Pharmaceutical compositions having appetite suppressant activity

Publications (2)

Publication Number Publication Date
EA199900932A1 true EA199900932A1 (ru) 2000-04-24
EA002885B1 EA002885B1 (ru) 2002-10-31

Family

ID=25586362

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199900932A EA002885B1 (ru) 1997-04-15 1998-04-15 Средства растительного происхождения для подавления аппетита
EA200200392A EA200200392A1 (ru) 1997-04-15 1998-04-15 Способ получения экстракта из растения рода trichocaulon или рода hoodia, экстракт, порошковый материал и композиция на его основе и их применение для производства медикамента для лечения, профилактики или преодоления ожирения и/или подавления аппетита

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200200392A EA200200392A1 (ru) 1997-04-15 1998-04-15 Способ получения экстракта из растения рода trichocaulon или рода hoodia, экстракт, порошковый материал и композиция на его основе и их применение для производства медикамента для лечения, профилактики или преодоления ожирения и/или подавления аппетита

Country Status (40)

Country Link
US (6) US6376657B1 (ru)
EP (5) EP0973534B1 (ru)
JP (3) JP3553086B2 (ru)
KR (2) KR100510614B1 (ru)
CN (3) CN101239089A (ru)
AP (3) AP2003002729A0 (ru)
AT (3) ATE422359T1 (ru)
AU (1) AU746414B2 (ru)
BG (1) BG103795A (ru)
BR (1) BR9808593A (ru)
CA (2) CA2283564C (ru)
DE (3) DE69840552D1 (ru)
DK (1) DK0973534T3 (ru)
EA (2) EA002885B1 (ru)
EE (1) EE9900497A (ru)
ES (3) ES2321162T3 (ru)
GB (3) GB2338235B (ru)
GE (2) GEP20022788B (ru)
GT (3) GT199800076AA (ru)
HK (1) HK1026373A1 (ru)
HU (1) HUP0000838A3 (ru)
ID (1) ID22888A (ru)
IL (3) IL131659A (ru)
IS (1) IS5196A (ru)
MY (1) MY141674A (ru)
NO (1) NO994992L (ru)
NZ (5) NZ337422A (ru)
OA (1) OA11166A (ru)
PE (1) PE85699A1 (ru)
PL (3) PL197783B1 (ru)
PT (2) PT1213020E (ru)
SA (1) SA98190501B1 (ru)
SG (1) SG120054A1 (ru)
SK (1) SK141899A3 (ru)
TR (2) TR199902540T2 (ru)
TW (3) TW589187B (ru)
UA (1) UA72439C2 (ru)
WO (1) WO1998046243A2 (ru)
YU (1) YU52199A (ru)
ZA (1) ZA983170B (ru)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840552D1 (de) * 1997-04-15 2009-03-26 Csir Verbindungen und Pharmazeutische Zusammensetzungen mit appetitunterdrückender Aktivität
EP1204645A2 (en) * 1999-08-04 2002-05-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
WO2003008660A1 (en) * 2001-07-19 2003-01-30 Trikon Holdings Limited Depositing a tantalum film
US7008648B2 (en) 2001-11-16 2006-03-07 Novartis Nutrition Ag Plant derived or derivable material with appetite suppressing activity
US20040265398A1 (en) * 2002-04-25 2004-12-30 Fleischner Albert M. Herbal composition for weight control
EP1594575A2 (en) * 2003-02-14 2005-11-16 Phytopharm Plc Modulation of atp production or content in the hypothalamus
US7060308B2 (en) * 2003-06-04 2006-06-13 Ramaswamy Rajendran Caralluma extract products and processes for making the same
US7976880B2 (en) * 2003-06-04 2011-07-12 Ramaswamy Rajendran Pregnane glycoside compositions and Caralluma extract products and uses thereof
EP1763358A4 (en) * 2004-04-07 2010-03-24 Univ Rutgers COMPOSITIONS AND METHODS CUT-HUNGER
GB0411703D0 (en) * 2004-05-25 2004-06-30 Phytopharm Plc Selective separation or extraction of steroidal glycosides
US20050276839A1 (en) * 2004-06-10 2005-12-15 Rifkin Calman H Appetite satiation and hydration beverage
US20050276869A1 (en) * 2004-06-14 2005-12-15 Century Systems Appetite-suppressing, lipase-inhibiting herbal composition
US7500679B2 (en) * 2004-10-08 2009-03-10 Wade James T Board for supporting front of snow vehicle
US20060083795A1 (en) * 2004-10-19 2006-04-20 Lima Shatkina Meal replacement products having appetite suppressing qualities
GB0425172D0 (en) * 2004-11-15 2004-12-15 Phyto Res Ltd Plant cells and uses thereof
CA2596311A1 (en) * 2005-01-20 2006-07-27 Stephen Holt Herbal compositions containing hoodia
US7247323B2 (en) * 2005-08-17 2007-07-24 Elc Management Llc Delivery system for appetite suppressant
US20070082030A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Fiber satiety compositions
US20070082114A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Methods for reducing weight
US20070082028A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Jr Compositions and methods for inducing satiety and reducing caloric intake
US20070082084A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Methods for weight management
US20070082029A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Fiber satiety compositions
US20070082085A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Compositions and methods for reducing food intake and controlling weight
US20070082108A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Jr Methods for reducing calorie intake
US20070082025A1 (en) * 2005-10-07 2007-04-12 Catani Steven J Methods for achieving and maintaining weight loss
US20070082026A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Jr Compositions and methods for reducing food intake and controlling weight
US20070082115A1 (en) * 2005-10-07 2007-04-12 Aimutis William Ronald Jr Methods for inducing satiety, reducing food intake and reducing weight
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US8945652B2 (en) 2005-11-23 2015-02-03 The Coca-Cola Company High-potency sweetener for weight management and compositions sweetened therewith
US20070207227A1 (en) * 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
US20070196436A1 (en) * 2006-02-23 2007-08-23 Conopco, Inc., D/B/A Unilever Process for preparing an edible composition comprising steroidal glycosides
CA2654286A1 (en) * 2006-06-13 2007-12-21 Unilever Plc Unit serving appetite suppressant compositions with steroidal glycosides
JP5281234B2 (ja) * 2006-06-27 2013-09-04 ポーラ化成工業株式会社 毛様体過緊張による疲れ目の改善・予防のための経口投与組成物
WO2008019920A1 (en) * 2006-08-17 2008-02-21 Unilever N.V. Processes for production of hoodia plant extracts containing steroidal glycosides
MX2009001866A (es) * 2006-08-24 2009-03-02 Unilever Nv Proceso para la preparacion de una composicion que comprende glucosidos esteroides.
US20080085354A1 (en) * 2006-10-06 2008-04-10 Teresa Marie Paeschke Controlled hydration of hydrocolloids
US20080138447A1 (en) * 2006-12-06 2008-06-12 Erin John Riggins Method for administering appetite suppressant and composition thereof
MX2009006449A (es) * 2006-12-21 2009-06-26 Unilever Nv Proceso para cosechar plantas de la familia apocynacea.
US20080188447A1 (en) * 2007-02-02 2008-08-07 Svyatoslav Komarnytsky Glucocorticoid-lowering composition
US8580236B2 (en) * 2007-03-19 2013-11-12 Richard P. De Maria Hair sustaining formulation
EP2052727A3 (en) * 2007-10-02 2010-06-02 Unilever N.V. Hoodia extract oil compositions comprising unsaturated monoacylglycerides
WO2009053980A2 (en) * 2007-10-24 2009-04-30 Arava Hoodia Growers A. C. S. Ltd. An improved appetite suppressant
US20090110774A1 (en) * 2007-10-26 2009-04-30 The Hershey Company High antioxidant levels in cocoa-based beverages
DE502007006794D1 (de) 2007-11-17 2011-05-05 Cognis Ip Man Gmbh Verfahren zur Herstellung von Wirkstoffkonzentraten
EP2080517A1 (en) * 2008-01-18 2009-07-22 Unilever N.V. Process for obtaining dried plant material
US20090324757A1 (en) * 2008-03-31 2009-12-31 Rutgers, The State University Of New Jersey Compositions and Methods for Modulating Visceral Sensation and/or Gastrointestinal Reflex Activity
JP5276885B2 (ja) * 2008-04-11 2013-08-28 株式会社耐熱性酵素研究所 キチン又はキトサンを含む分解性複合材料
US20090263510A1 (en) 2008-04-21 2009-10-22 Conopco, Inc., D/B/A Unilever Process of making Hoodia plant extract with improved flavor
US7923435B2 (en) * 2008-04-21 2011-04-12 Phytopharm Plc Hoodia plant extract with improved flavor
EP2373324A1 (en) 2008-12-08 2011-10-12 Hadasit Medical Research Services & Development Limited Method of treatment of diseases using hoodia extracts
US20110003021A1 (en) 2009-07-01 2011-01-06 Jason Christian Grovenor Halford Composition and method for reducing food intake
EP2329836A1 (en) 2009-12-03 2011-06-08 I.R.B. Istituto Di Ricerche Biotecnologiche S.r.l. Extracts obtained from hoodia gordonii cells lines, their preparation and use
CA2827050A1 (en) * 2010-02-18 2011-08-25 The Hershey Company Cocoa-based exercise recovery beverages
WO2012022880A2 (fr) 2010-07-29 2012-02-23 Universite De Strasbourg Procede de synthese de steroïdes
CN102462690B (zh) * 2010-11-11 2013-04-17 中国科学院上海药物研究所 3，8，12，14，17，20位氧取代孕甾烯糖苷类化合物在制备抑制食欲的药物中的用途
JP6114695B2 (ja) 2010-12-20 2017-04-12 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 満腹応答を誘導するためのペットフード組成物
JP2014501787A (ja) 2011-01-07 2014-01-23 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
US9456916B2 (en) 2013-03-12 2016-10-04 Medibotics Llc Device for selectively reducing absorption of unhealthy food
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
SG10201705437SA (en) 2013-01-05 2017-07-28 Elcelyx Therapeutics Inc Delayed-release composition comprising biguanide
US9067070B2 (en) 2013-03-12 2015-06-30 Medibotics Llc Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type
US9011365B2 (en) 2013-03-12 2015-04-21 Medibotics Llc Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food
US20160176914A1 (en) * 2013-05-29 2016-06-23 Northeastern University Glycosylated cardiotonic steroids
CN103755762B (zh) * 2014-01-30 2016-06-01 中国科学院上海有机化学研究所 果同尼皂苷f及其衍生物的中间体、制备方法和用途及果同尼皂苷f衍生物
GB2544416B (en) * 2015-11-13 2017-11-01 Lykke Res Ltd A method for producing a medium containing steroidal glycosides from plant cells of the genus Hoodia

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
FR2348655A1 (fr) 1976-04-20 1977-11-18 Sopharga Lab Nouvelle substance alimentaire ou dietetique ayant une structure alveolaire et son procede de preparation
US4185116A (en) 1976-09-28 1980-01-22 Pfizer Inc. L- and DL- Phenylglycines to treat diseases or conditions attributable to reduced carbohydrate metabolism
USPP4199P (en) 1977-01-18 1978-01-24 B. L. Cobia, Inc. Milkweed plant family
DE2719912C3 (de) * 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
US4130714A (en) 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4791126A (en) * 1980-08-22 1988-12-13 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients
DE3166093D1 (en) * 1981-01-05 1984-10-18 Takeda Chemical Industries Ltd N-substituted pseudo-aminosugars, their production and use
CA1176269A (en) 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4377500A (en) 1981-07-08 1983-03-22 The Standard Oil Co. Catalysts
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
JPS58194818A (ja) 1982-05-10 1983-11-12 Iwasaki Shuzo サボテン中の水溶性多糖及び繊維の取得方法
ES8404693A1 (es) 1982-08-12 1984-05-01 Nativelle Sa Ets Procedimiento de preparacion de nuevos amino-14 esteroides.
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
HU201675B (en) 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US4634765A (en) * 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
US5246960A (en) 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
IT1207504B (it) 1985-09-26 1989-05-25 Crinos Industria Farmaco Composizione moderatrice dell'appetito ed antigastrica.
IT1190400B (it) 1985-10-04 1988-02-16 Istituto Biochimico Italiano Derivati dell'acido 19,20-bis,nor-prostanoico ad attivita' antiulcera e anoressivca,procedimento per la loro preparazione e composizioni farmaceutiche
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4757151A (en) 1985-11-14 1988-07-12 Warner-Lambert Company 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
US4652553A (en) 1985-11-25 1987-03-24 Merck & Co., Inc. Steroidal glycolipids as host resistance stimulators
GB8600489D0 (en) 1986-01-09 1986-02-12 Erba Farmitalia Aminoglycoside steroids
AU602641B2 (en) * 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use
DE3769066D1 (de) 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
ZA883929B (en) 1987-06-22 1990-02-28 Hoffmann La Roche Cholecystokinin analogs for controlling appetite
US5175154A (en) 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
US5192772A (en) 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
GB8801037D0 (en) * 1988-01-18 1988-02-17 Plessey Co Ltd Improvements relating to fuel supply systems
US5252572A (en) * 1988-02-03 1993-10-12 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
EP0344383A1 (en) 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Novel alpha-Glucosidase inhibitors
DE3836675A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung
US4978669A (en) 1989-06-08 1990-12-18 Neurex Corporation Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives
JPH03120227A (ja) 1989-10-02 1991-05-22 Shigeo Ochi 飲食物消化分解産物吸収抑制剤
US4980357A (en) * 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5037831A (en) 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
US5504078A (en) * 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
US5217877A (en) 1990-09-28 1993-06-08 Bristol-Myers Squibb Company Process for the preparation of α-glucosidase inhibitor, pradimicin Q
US5091418A (en) 1990-09-28 1992-02-25 Bristol-Myers Squibb Company Novel alpha-glucosidase inhibitor, pradimicin Q
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
CA2145640C (en) 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
NZ256251A (en) 1992-09-30 1995-12-21 Motorola Inc High reliability message pager: missed messages requested and retransmitted over alternative channel
GB9307833D0 (en) 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
AU7174494A (en) 1993-06-18 1995-01-17 University Of Cincinnati, The Neuropeptide y antagonists and agonists
US5516516A (en) 1993-10-19 1996-05-14 Cherksey; Bruce D. Method of preparing muira puama extract and its use for decreasing body fat percentage and increasing lean muscle mass
JPH07184548A (ja) * 1993-12-28 1995-07-25 Meiji Seito Kk 口腔用組成物
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5698199A (en) 1995-03-10 1997-12-16 Kao Corporation Lipolysis acceleration method
EP0832065B1 (en) 1995-06-06 2001-10-10 Pfizer Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
EP0832066B1 (en) 1995-06-06 2001-09-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
JPH08332028A (ja) 1995-06-12 1996-12-17 Takashi Mizuno サボテン成分入り冷菓とその製法
US5693327A (en) 1995-07-12 1997-12-02 Shah; Eladevi Herbal compositions
CA2238940A1 (en) 1995-10-26 1997-05-01 Board Of Regents, The University Of Texas System Luminal cholecystokinin-releasing factor
US5824668A (en) 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US5932779A (en) 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5908609A (en) 1996-06-10 1999-06-01 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
AU5243798A (en) 1996-11-06 1998-05-29 Children's Medical Center Corporation Transgenic animal expressing a syndecan in the regions of hypothalamus
JP2001506996A (ja) 1996-12-17 2001-05-29 クアドラント ホールディングス ケンブリッジ リミテッド メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体
CA2217698A1 (en) 1996-12-20 1998-06-20 Eli Lilly And Company Anti-obesity proteins
US5798101A (en) 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
WO1998042747A1 (en) 1997-03-26 1998-10-01 Novo Nordisk A/S Polypeptide with appetite regulating activity
DE69840552D1 (de) * 1997-04-15 2009-03-26 Csir Verbindungen und Pharmazeutische Zusammensetzungen mit appetitunterdrückender Aktivität
FR2771105A1 (fr) 1997-11-20 1999-05-21 Vitasterol Utilisation du fusarium monoliforme pour la preparation des derives 7alpha-hydroxyles de la dehydroepiandrosterone et de la pregnenolone
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use

Also Published As

Publication number Publication date
AP2003002729A0 (en) 2003-06-30
DE69842189D1 (de) 2011-04-28
JP3553086B2 (ja) 2004-08-11
AU746414B2 (en) 2002-05-02
DE69840552D1 (de) 2009-03-26
US20020168427A1 (en) 2002-11-14
WO1998046243A2 (en) 1998-10-22
CA2283564C (en) 2007-07-10
JP2000510482A (ja) 2000-08-15
EP0973534A1 (en) 2000-01-26
EA002885B1 (ru) 2002-10-31
AP9901673A0 (en) 1999-12-31
NO994992L (no) 1999-12-14
KR100510614B1 (ko) 2005-08-30
GB2360520A (en) 2001-09-26
BG103795A (en) 2000-05-31
NO994992D0 (no) 1999-10-14
PL201487B1 (pl) 2009-04-30
GB2338235A (en) 1999-12-15
AP1291A (en) 2004-08-02
GB0117039D0 (en) 2001-09-05
DK0973534T3 (da) 2007-03-12
EP1222927B1 (en) 2013-11-20
NZ525022A (en) 2004-05-28
TW539551B (en) 2003-07-01
IL158465A0 (en) 2004-05-12
KR100891756B1 (ko) 2009-04-07
US20040234634A1 (en) 2004-11-25
CA2584411A1 (en) 1998-10-22
PT1213020E (pt) 2009-04-24
UA72439C2 (en) 2005-03-15
SK141899A3 (en) 2000-09-12
GEP20022788B (en) 2002-09-25
CN101239090A (zh) 2008-08-13
EP0973534B1 (en) 2006-11-02
GB9919797D0 (en) 1999-10-27
HUP0000838A3 (en) 2001-04-28
SA98190501B1 (ar) 2006-07-30
TW200300094A (en) 2003-05-16
ES2321162T3 (es) 2009-06-03
ID22888A (id) 1999-12-16
CN101239089A (zh) 2008-08-13
SG120054A1 (en) 2006-03-28
PT973534E (pt) 2007-02-28
OA11166A (en) 2003-04-28
EP1222927A2 (en) 2002-07-17
PL196015B1 (pl) 2007-11-30
US20060205931A1 (en) 2006-09-14
EP1213020B1 (en) 2009-02-11
GB2360519A (en) 2001-09-26
GB0117041D0 (en) 2001-09-05
EP1222927A3 (en) 2002-10-30
CN1252000A (zh) 2000-05-03
HK1026373A1 (en) 2000-12-15
EP1213020A2 (en) 2002-06-12
EP1213020A8 (en) 2003-12-17
TW200300093A (en) 2003-05-16
CN100378118C (zh) 2008-04-02
KR20010006424A (ko) 2001-01-26
ATE344046T1 (de) 2006-11-15
NZ516695A (en) 2003-08-29
NZ337422A (en) 2002-05-31
EA200200392A1 (ru) 2002-08-29
EP1598054A3 (en) 2009-06-10
ATE502041T1 (de) 2011-04-15
ES2363230T3 (es) 2011-07-27
TWI253932B (en) 2006-05-01
DE69836321D1 (de) 2006-12-14
DE69836321T2 (de) 2007-06-28
EP1438965A1 (en) 2004-07-21
EP1598054A2 (en) 2005-11-23
GT199800076A (es) 1999-12-01
GT199800076AA (es) 1999-12-01
AU7061398A (en) 1998-11-11
IS5196A (is) 1999-09-24
US20040228935A1 (en) 2004-11-18
BR9808593A (pt) 2000-05-23
TR200001846T2 (tr) 2000-11-21
ZA983170B (en) 1999-10-15
JP2003026591A (ja) 2003-01-29
NZ516696A (en) 2003-08-29
GEP20022709B (en) 2002-06-25
IL131659A (en) 2005-07-25
CA2283564A1 (en) 1998-10-22
US6376657B1 (en) 2002-04-23
IL131659A0 (en) 2001-01-28
MY141674A (en) 2010-05-31
EP1213020A3 (en) 2005-03-09
NZ525021A (en) 2004-05-28
HUP0000838A2 (hu) 2000-10-28
PE85699A1 (es) 1999-09-15
EE9900497A (et) 2000-06-15
US7166611B2 (en) 2007-01-23
GT199800076BA (es) 1999-12-01
EP1598054B1 (en) 2011-03-16
GB2360519B (en) 2001-11-28
YU52199A (sh) 2003-02-28
KR20040004407A (ko) 2004-01-13
AP2003002730A0 (en) 2003-06-30
ES2276460T3 (es) 2007-06-16
TR199902540T2 (xx) 2000-01-21
TW589187B (en) 2004-06-01
JP2002205997A (ja) 2002-07-23
IL158466A0 (en) 2004-05-12
ATE422359T1 (de) 2009-02-15
GB2360520B (en) 2001-11-07
PL336498A1 (en) 2000-07-03
US20030086984A1 (en) 2003-05-08
GB2338235B (en) 2001-11-14
WO1998046243A3 (en) 1999-02-25
PL197783B1 (pl) 2008-04-30

Similar Documents

Publication Publication Date Title
EA199900932A1 (ru) Фармацевтические композиции, обладающие активностью подавления аппетита
GB2363985B (en) Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
DE69831868D1 (en) Antithrombosemittel
ATE297203T1 (de) Antithrombotische mitteln
YU149791A (sh) Mometason, furoat monohidrat i postupak za njegovo dobijanje
CA2124932A1 (en) Sex steroid activity inhibitors
IL107870A0 (en) Pharmaceutical compositions having antidepressant activity comprising pramipexol
JPS5665869A (en) Novel 22hydroxyalkyll3*4*55trihydroxyypiperidine compound* its manufacture and drug
AR001354A1 (es) Compuestos bi-aromaticos derivados de amida, composiciones farmacéuticas y cosméticas que los contien, y utilización de dichos compuestos y composición cosmética.
PE45195A1 (es) Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
FR2763592B1 (fr) Nouveaux derives glycosyles des ginkgolides, leur application en tant que medicaments et compositions pharmaceutiques les contenant
FR2690847B1 (fr) Compositions a activite agoniste des recepteurs analogues a 5ht1 selective.
ECSP982540A (es) Composiciones farmaceuticas que tienen actividad supresora del apetito
PA8458401A1 (es) Composiciones farmaceuticas que tienen actividad supresora del apetito
EE200200302A (et) Küllastumata 14,15-tsüklopropanoandrostaanid, nende valmistamise meetod ja neid ühendeid sisaldavadfarmatseutilised kompositsioonid
HUP9603341A2 (hu) Véralvadásgátló hatású glikozidok és az ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU